This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

XenoPort, Inc. (XNPT)

Morgan Stanley Healthcare Conference

September 11, 2012 03:00 pm ET


Ron Barrett - Chief Executive Officer and Director


David Friedman - Morgan Stanley


David Friedman - Morgan Stanley

All right, so I think we'll get started. Thanks everyone for joining us and I'm David Friedman, Biotech Analyst here. In terms of our disclosure statement, you can find research disclosures at, and I am joined by Ron Barrett here, CEO of XenoPort, and one of the best performing stocks in all of small and midcap biotech this year, so a lot going on and I would to go into it, so maybe if you can just a one or two-minute overview of the company, and then we can just jump right into the program.

Ron Barrett

Sure. Thanks for the invitation to speak today and I am going to be making forward-looking statements and you should consult SEC documents with information with regard to risks and uncertainties of our business.

XenoPort, it's a very interesting time for the company. We have a series of products and product candidates that are in different stages and walk through them one at a time. Our gabapentin enacarbil is an approved product in the U.S. and Japan, and Horizant is the trade name in the U.S. and Regnite in Japan.

It's approved for the treatment of moderate-to-severe primary RLS in the U.S. and Japan, and also for postherpetic neuralgia in the U.S. we are partnered with GSK in the U.S. and Astellas in Japan, and I would say that I really don't have an update on Horizant's. It launched last July. The sales have been blockbuster and it's been very frustrating for us as a company, and as you undoubtedly know we are in litigations with GSK, I don't really have any update on the litigation today.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs